# Revolution Medicines, Inc. (RVMD) FY2024 Q3 Balance Sheet

- Company: Revolution Medicines, Inc. (RVMD)
- Period: As of 2024-09-30
- Filing: Q3 FY2024 10-Q, filed 2024-11-06, accession number 0000950170-24-122303
- Page: https://plicit.ai/financials/rvmd/fy2024-q3-balance-sheet
- Chart image: https://plicit.ai/charts/rvmd-fy2024-q3-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2024-09-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 1,762,999,000 US dollars
- **Current assets**: 1,579,139,000 US dollars
- **Non-current assets**: 183,860,000 US dollars
- **Liabilities**: 196,695,000 US dollars
- **Current liabilities**: 110,863,000 US dollars
- **Non-current liabilities**: 85,832,000 US dollars
- **Equity**: 1,566,304,000 US dollars
- **Marketable securities**: 1,348,219,000 US dollars
- **Cash and cash equivalents**: 201,262,000 US dollars
- **Prepaid expenses and other current assets**: 29,658,000 US dollars
- **Accounts receivable**: 0 US dollars
- **Operating lease right-of-use asset**: 74,338,000 US dollars
- **Intangible assets, net**: 56,937,000 US dollars
- **Property and equipment, net**: 24,814,000 US dollars
- **Goodwill**: 14,608,000 US dollars
- **Other noncurrent assets**: 10,275,000 US dollars
- **Restricted cash**: 2,888,000 US dollars
- **Accrued expenses and other current liabilities**: 78,011,000 US dollars
- **Accounts payable**: 24,456,000 US dollars
- **Operating lease liability, current**: 8,396,000 US dollars
- **Operating lease liability, noncurrent**: 78,310,000 US dollars
- **Deferred tax liability**: 3,115,000 US dollars
- **Warrant liabilities**: 2,763,000 US dollars
- **Other noncurrent liabilities**: 1,644,000 US dollars
- **Additional paid-in capital**: 3,105,708,000 US dollars
- **Accumulated other comprehensive income**: 3,812,000 US dollars
- **Common stock, $0.0001 par value; 300,000,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively; 173,308,336 and 170,234,594 shares issued as of September 30, 2024 and December 31, 2023, respectively; 167,748,336 and 164,674,594 shares outstanding as of September 30, 2024 and December 31, 2023, respectively**: 16,000 US dollars
- **Preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2024 and December 31, 2023, respectively; none issued and outstanding at September 30, 2024 and December 31, 2023, respectively**: 0 US dollars
- **Accumulated deficit**: negative 1,543,232,000 US dollars
- **Gross equity (calculated)**: 3,109,536,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.